A comprehensive view of AbbVie Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

In the migraine treatment drug market, Q2 sales of Lilly’s Emgality hit US$157.5M, AbbVies’s Ubrelvy sales total US$138.0M, Biohaven’s Nurtec has US$123.6M in sales; Amgen’s Aimovig records US$92.0M in sales in Q2

AbbVie reports Q2 net profit up at US$924.0M from US$766.0M a year ago, with revenue up 4.5% year-over-year to US$14.58B; growth driven by immunology and neuroscience portfolios, while aesthetic and blood cancer treatments declined

AbbVie terminates program for experimental Alzheimer’s injectable drug AL003 it co-developed with Alector; the two companies to continue work on experimental Alzheimer’s drug AL002

AbbVie submits supplemental new drug application to FDA for Atogepant Qulipt, a preventive treatment for chronic migraines in adults; migraines affect 39 million people in US, are highest cause of disability for those under 50 years of age

FDA approves AbbVie’s Skyrizi injectable to treat moderate to severe active Crohn's disease in adults; drug is first new treatment for moderate to severe active CD in six years

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count